| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 41 | 2025 | 765 | 8.270 |
Why?
|
| United States Department of Veterans Affairs | 25 | 2025 | 544 | 2.990 |
Why?
|
| Depression, Postpartum | 11 | 2024 | 129 | 2.730 |
Why?
|
| Maternal Health Services | 8 | 2025 | 66 | 2.200 |
Why?
|
| Pregnancy | 38 | 2025 | 2338 | 2.010 |
Why?
|
| Veterans Health | 12 | 2025 | 158 | 1.770 |
Why?
|
| Musculoskeletal Pain | 2 | 2024 | 28 | 1.680 |
Why?
|
| Prenatal Care | 6 | 2021 | 170 | 1.580 |
Why?
|
| Depression | 12 | 2023 | 894 | 1.560 |
Why?
|
| Military Personnel | 7 | 2024 | 120 | 1.510 |
Why?
|
| Mental Health Services | 5 | 2022 | 287 | 1.380 |
Why?
|
| Qualitative Research | 6 | 2025 | 689 | 1.220 |
Why?
|
| Pregnancy Complications | 5 | 2024 | 378 | 1.210 |
Why?
|
| Doulas | 2 | 2025 | 7 | 1.180 |
Why?
|
| United States | 31 | 2025 | 7842 | 1.160 |
Why?
|
| Cesarean Section | 3 | 2024 | 101 | 1.150 |
Why?
|
| Chronic Pain | 2 | 2024 | 154 | 1.140 |
Why?
|
| Female | 65 | 2025 | 32889 | 1.090 |
Why?
|
| Postpartum Period | 6 | 2024 | 195 | 1.020 |
Why?
|
| Adult | 42 | 2025 | 16830 | 0.940 |
Why?
|
| Depressive Disorder, Major | 3 | 2023 | 255 | 0.920 |
Why?
|
| Personal Autonomy | 1 | 2024 | 68 | 0.840 |
Why?
|
| Health Services Accessibility | 7 | 2024 | 564 | 0.840 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2024 | 397 | 0.830 |
Why?
|
| Humans | 72 | 2025 | 63467 | 0.800 |
Why?
|
| Mothers | 3 | 2024 | 275 | 0.790 |
Why?
|
| Infertility | 1 | 2023 | 31 | 0.780 |
Why?
|
| Evidence-Based Practice | 1 | 2023 | 85 | 0.780 |
Why?
|
| Racism | 1 | 2024 | 88 | 0.770 |
Why?
|
| Pain Management | 1 | 2024 | 161 | 0.760 |
Why?
|
| Peripartum Period | 4 | 2020 | 21 | 0.760 |
Why?
|
| Mental Health | 7 | 2023 | 371 | 0.700 |
Why?
|
| Perinatal Care | 4 | 2022 | 64 | 0.690 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2019 | 125 | 0.680 |
Why?
|
| Anxiety | 3 | 2023 | 425 | 0.680 |
Why?
|
| Burnout, Professional | 1 | 2022 | 135 | 0.660 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2023 | 77 | 0.660 |
Why?
|
| Smoking Cessation | 2 | 2021 | 550 | 0.580 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 174 | 0.570 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 536 | 0.560 |
Why?
|
| Telemedicine | 1 | 2022 | 326 | 0.550 |
Why?
|
| Sex Offenses | 3 | 2024 | 47 | 0.530 |
Why?
|
| Oxytocics | 1 | 2017 | 14 | 0.520 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 194 | 0.520 |
Why?
|
| Cohort Studies | 9 | 2024 | 2569 | 0.520 |
Why?
|
| Oxytocin | 1 | 2017 | 45 | 0.510 |
Why?
|
| Infant, Newborn | 7 | 2023 | 1358 | 0.500 |
Why?
|
| Premenstrual Syndrome | 2 | 2017 | 99 | 0.500 |
Why?
|
| Prescription Drugs | 1 | 2015 | 51 | 0.460 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 192 | 0.460 |
Why?
|
| Infant | 6 | 2023 | 1648 | 0.440 |
Why?
|
| Young Adult | 11 | 2020 | 4696 | 0.440 |
Why?
|
| Middle Aged | 20 | 2025 | 17609 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2023 | 480 | 0.410 |
Why?
|
| Interviews as Topic | 2 | 2024 | 514 | 0.370 |
Why?
|
| Adolescent | 11 | 2019 | 6253 | 0.340 |
Why?
|
| Exercise | 1 | 2017 | 942 | 0.310 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 596 | 0.290 |
Why?
|
| Women's Health | 2 | 2025 | 370 | 0.280 |
Why?
|
| Health Personnel | 2 | 2022 | 366 | 0.280 |
Why?
|
| Prevalence | 4 | 2021 | 1380 | 0.270 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2018 | 75 | 0.260 |
Why?
|
| Organ Transplantation | 2 | 2020 | 54 | 0.250 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 2576 | 0.250 |
Why?
|
| Iraq War, 2003-2011 | 5 | 2019 | 66 | 0.250 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 2679 | 0.250 |
Why?
|
| Male | 18 | 2025 | 29906 | 0.230 |
Why?
|
| Drug Prescriptions | 2 | 2017 | 168 | 0.230 |
Why?
|
| Child | 7 | 2024 | 4534 | 0.230 |
Why?
|
| Afghan Campaign 2001- | 4 | 2019 | 70 | 0.220 |
Why?
|
| Suicide, Attempted | 1 | 2025 | 107 | 0.220 |
Why?
|
| Sexual Harassment | 2 | 2023 | 15 | 0.210 |
Why?
|
| Interleukin-13 | 1 | 2023 | 37 | 0.210 |
Why?
|
| Women | 1 | 2024 | 44 | 0.210 |
Why?
|
| Health Services Research | 1 | 2025 | 271 | 0.210 |
Why?
|
| Stress, Psychological | 2 | 2019 | 470 | 0.210 |
Why?
|
| Public Policy | 1 | 2023 | 41 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 60 | 0.200 |
Why?
|
| Perception | 1 | 2024 | 174 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2019 | 390 | 0.200 |
Why?
|
| Abortion, Spontaneous | 1 | 2023 | 31 | 0.200 |
Why?
|
| Age Factors | 3 | 2023 | 1559 | 0.200 |
Why?
|
| Community Health Services | 2 | 2021 | 128 | 0.200 |
Why?
|
| Pentoxifylline | 1 | 2022 | 8 | 0.190 |
Why?
|
| Abortion, Induced | 1 | 2022 | 27 | 0.190 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2022 | 11 | 0.190 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 225 | 0.190 |
Why?
|
| Mental Disorders | 3 | 2019 | 791 | 0.190 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 10 | 0.190 |
Why?
|
| End Stage Liver Disease | 1 | 2022 | 33 | 0.190 |
Why?
|
| Pilot Projects | 1 | 2025 | 1008 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2022 | 137 | 0.180 |
Why?
|
| Premature Birth | 1 | 2023 | 112 | 0.180 |
Why?
|
| Breast Feeding | 1 | 2024 | 151 | 0.180 |
Why?
|
| Soft Tissue Infections | 1 | 2022 | 49 | 0.180 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 11 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 65 | 0.180 |
Why?
|
| Community-Acquired Infections | 1 | 2022 | 94 | 0.180 |
Why?
|
| Community Networks | 1 | 2021 | 31 | 0.180 |
Why?
|
| Patient Selection | 1 | 2024 | 490 | 0.180 |
Why?
|
| Bacteremia | 1 | 2022 | 94 | 0.170 |
Why?
|
| Vaccines | 1 | 2022 | 97 | 0.170 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 129 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 456 | 0.170 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 26 | 0.170 |
Why?
|
| Pandemics | 2 | 2022 | 671 | 0.170 |
Why?
|
| Prospective Studies | 7 | 2022 | 3294 | 0.170 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1256 | 0.170 |
Why?
|
| Decision Making | 1 | 2024 | 407 | 0.170 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 15 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 24 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 44 | 0.160 |
Why?
|
| HIV | 1 | 2020 | 70 | 0.160 |
Why?
|
| Counseling | 1 | 2022 | 362 | 0.160 |
Why?
|
| Health Status | 2 | 2019 | 436 | 0.160 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 13 | 0.160 |
Why?
|
| Risk Factors | 9 | 2022 | 5356 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2020 | 153 | 0.150 |
Why?
|
| Health Policy | 1 | 2021 | 192 | 0.150 |
Why?
|
| Acute-Phase Proteins | 1 | 2019 | 34 | 0.150 |
Why?
|
| Smoking | 2 | 2021 | 866 | 0.150 |
Why?
|
| Health Services | 1 | 2019 | 82 | 0.150 |
Why?
|
| Creatine | 1 | 2018 | 24 | 0.150 |
Why?
|
| Sexual Partners | 1 | 2019 | 76 | 0.150 |
Why?
|
| Macrophage Activation | 1 | 2019 | 119 | 0.150 |
Why?
|
| Hepacivirus | 1 | 2020 | 141 | 0.150 |
Why?
|
| Gyrus Cinguli | 1 | 2018 | 57 | 0.150 |
Why?
|
| Connectome | 1 | 2018 | 33 | 0.140 |
Why?
|
| Alcoholism | 1 | 2021 | 318 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 347 | 0.140 |
Why?
|
| Sperm Count | 1 | 2017 | 15 | 0.140 |
Why?
|
| Recreation | 1 | 2017 | 21 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 262 | 0.130 |
Why?
|
| Semen | 1 | 2017 | 48 | 0.130 |
Why?
|
| Disease Progression | 2 | 2019 | 1172 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2017 | 57 | 0.130 |
Why?
|
| Prognosis | 3 | 2019 | 1748 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 55 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 422 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2018 | 311 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 669 | 0.120 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 21 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 448 | 0.120 |
Why?
|
| Mass Screening | 3 | 2020 | 690 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2017 | 866 | 0.120 |
Why?
|
| Length of Stay | 2 | 2020 | 813 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1228 | 0.120 |
Why?
|
| Rehabilitation Centers | 1 | 2015 | 14 | 0.110 |
Why?
|
| Infertility, Female | 1 | 2015 | 46 | 0.110 |
Why?
|
| Logistic Models | 2 | 2015 | 1277 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 4 | 0.110 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1121 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2022 | 6659 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2017 | 768 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2019 | 707 | 0.110 |
Why?
|
| Pregnanolone | 3 | 2020 | 14 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2015 | 36 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2016 | 193 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 836 | 0.110 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 83 | 0.110 |
Why?
|
| Longevity | 1 | 2015 | 113 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 68 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 12 | 0.100 |
Why?
|
| Sertraline | 1 | 2013 | 58 | 0.100 |
Why?
|
| Weight Gain | 1 | 2014 | 169 | 0.100 |
Why?
|
| Fetus | 1 | 2013 | 99 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2019 | 690 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 39 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2013 | 100 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 103 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 57 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2017 | 5685 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2013 | 100 | 0.100 |
Why?
|
| Perimenopause | 1 | 2012 | 31 | 0.090 |
Why?
|
| Weight Loss | 1 | 2014 | 273 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 246 | 0.090 |
Why?
|
| Body Weight | 1 | 2013 | 379 | 0.090 |
Why?
|
| Parturition | 2 | 2023 | 55 | 0.090 |
Why?
|
| Sleep | 1 | 2014 | 225 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 1553 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 443 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 203 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 281 | 0.090 |
Why?
|
| Postmenopause | 1 | 2012 | 237 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2012 | 192 | 0.080 |
Why?
|
| Aged | 9 | 2019 | 14443 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 275 | 0.080 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 247 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 322 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1364 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2014 | 242 | 0.080 |
Why?
|
| 20-alpha-Dihydroprogesterone | 2 | 2020 | 7 | 0.070 |
Why?
|
| Desoxycorticosterone | 2 | 2020 | 7 | 0.070 |
Why?
|
| Progesterone | 2 | 2020 | 163 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 5462 | 0.060 |
Why?
|
| Aging | 1 | 2012 | 745 | 0.060 |
Why?
|
| Biomarkers | 2 | 2023 | 1408 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 422 | 0.060 |
Why?
|
| Psychotherapy, Group | 1 | 2025 | 34 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 937 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 149 | 0.060 |
Why?
|
| Depressive Disorder | 2 | 2020 | 284 | 0.050 |
Why?
|
| Lipocalin-2 | 1 | 2023 | 9 | 0.050 |
Why?
|
| alpha-Fetoproteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| Rape | 1 | 2023 | 15 | 0.050 |
Why?
|
| Program Development | 1 | 2025 | 207 | 0.050 |
Why?
|
| Focus Groups | 1 | 2025 | 303 | 0.050 |
Why?
|
| Gender Identity | 1 | 2024 | 67 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 17 | 0.050 |
Why?
|
| Employment | 1 | 2024 | 127 | 0.050 |
Why?
|
| Birth Weight | 1 | 2023 | 85 | 0.050 |
Why?
|
| Fertilization | 1 | 2023 | 81 | 0.050 |
Why?
|
| Fertilization in Vitro | 1 | 2023 | 85 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2022 | 35 | 0.050 |
Why?
|
| Leukocidins | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exotoxins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 30 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 509 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 321 | 0.050 |
Why?
|
| Lactation | 1 | 2022 | 69 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 66 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 187 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2022 | 61 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2022 | 102 | 0.050 |
Why?
|
| Zinc | 1 | 2022 | 92 | 0.050 |
Why?
|
| Sex Factors | 2 | 2015 | 980 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 771 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 176 | 0.040 |
Why?
|
| Object Attachment | 1 | 2020 | 19 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2025 | 435 | 0.040 |
Why?
|
| Pregnenolone | 1 | 2020 | 4 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 182 | 0.040 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 46 | 0.040 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 20 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 11 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2021 | 287 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 131 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 37 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2020 | 32 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2021 | 198 | 0.040 |
Why?
|
| New Jersey | 1 | 2019 | 26 | 0.040 |
Why?
|
| Texas | 1 | 2019 | 57 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 363 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 147 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 54 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 40 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 134 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2019 | 90 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 282 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2019 | 117 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 221 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2020 | 151 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 454 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 371 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 583 | 0.030 |
Why?
|
| Parents | 1 | 2021 | 392 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 201 | 0.030 |
Why?
|
| Marital Status | 1 | 2017 | 45 | 0.030 |
Why?
|
| Semen Analysis | 1 | 2017 | 20 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 730 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 317 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 753 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 25 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1094 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 410 | 0.030 |
Why?
|
| Saliva | 1 | 2016 | 103 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 433 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 27 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 519 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 82 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 86 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 406 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 99 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 123 | 0.030 |
Why?
|
| Hallucinations | 1 | 2013 | 16 | 0.030 |
Why?
|
| Metabolism | 1 | 2013 | 13 | 0.030 |
Why?
|
| Massachusetts | 1 | 2019 | 2075 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 120 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 17 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2013 | 121 | 0.020 |
Why?
|
| Family | 1 | 2015 | 238 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 35 | 0.020 |
Why?
|
| HIV Infections | 1 | 2020 | 969 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1644 | 0.020 |
Why?
|
| Overweight | 1 | 2014 | 250 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 201 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 464 | 0.020 |
Why?
|
| Premenopause | 1 | 2012 | 60 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2081 | 0.020 |
Why?
|
| Global Health | 1 | 2013 | 183 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 81 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 373 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 739 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2015 | 407 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 125 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 397 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 778 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2015 | 512 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 852 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 301 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1148 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 351 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2176 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1377 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2462 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 1361 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 1309 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 2609 | 0.010 |
Why?
|